Proto Labs Inc : Doug Kohrs to join Proto Labs Board of Directors
04/03/2012| 01:20pm US/Eastern
Proto Labs, Inc. (NYSE: PRLB), a leading online and technology-enabled
quick-turn manufacturer, today announced that Doug Kohrs, President and
CEO of Tornier, N.V., a global medical device company, was appointed to
its Board of Directors, bringing the board's size to 9 members.
"Doug has impressive leadership experience with a variety of highly
successful, technology-based public companies, said Brad Cleveland,
President and CEO of Proto Labs. "We are excited to welcome Doug to our
Board and look forward to benefitting from his insights."
Prior to joining Tornier, Mr. Kohrs served as President and Chief
Executive Officer of American Medical Systems Holdings, Inc., a publicly
held medical device company that was acquired by Endo Pharmaceuticals
Holdings, Inc. Mr. Kohrs also served as Chairman of the Board of
American Medical Systems Holdings.
During the past 10 years, Mr. Kohrs has served on the board of directors
of nine different medical device companies, including ev3 Inc., a
publicly held medical device company that was acquired by a wholly-owned
subsidiary of Covidien Group S.a.r.l, and Kyphon, Inc., a publicly held
medical device company that was acquired by Medtronic, Inc.
Mr. Kohrs holds a Master of Business Administration from Northeastern
University, a Bachelor of Science in Bioengineering from Texas A&M
University and a Bachelor of Arts in Engineering Sciences from Austin
About Proto Labs, Inc.
Proto Labs is a leading online and
technology-enabled quick-turn manufacturer of custom parts for
prototyping and short-run production. Proto Labs provides "Real Parts,
Really Fast" to product developers worldwide. Proto Labs utilizes
computer numerical control (CNC) machining and injection molding to
manufacture custom parts for our customers. For more information, visit protolabs.com.
Cautionary Note Regarding Forward-Looking Statements
contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of
The Private Securities Litigation Reform Act of 1995. These statements
involve known and unknown risks, uncertainties and other factors which
may cause the results of Proto Labs to be materially different than
those expressed or implied in such statements. Certain of these risk
factors and others are described in the "Risk Factors" section of the
final prospectus relating to the initial public offering, as filed with
the SEC, as well as in Proto Labs' subsequent reports filed with the
SEC. Other unknown or unpredictable factors also could have material
adverse effects on Proto Labs' future results. The forward-looking
statements included in this press release are made only as of the date
hereof. Proto Labs cannot guarantee future results, levels of activity,
performance or achievements. Accordingly, you should not place undue
reliance on these forward-looking statements. Finally, Proto Labs
expressly disclaims any intent or obligation to update any
forward-looking statements to reflect subsequent events or circumstances.
Proto Labs, Inc.
Bill Dietrick, 763-479-7664
for Proto Labs, Inc.
Mike Stephenson, 612-767-7632
© Business Wire 2012